Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Lupin and Huons Sign agreement for commercialization of cyclosporine ophthalmic nanoemulsion in Mexico

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome

Merck to acquire EyeBio for US$ 1.3 billion upfront payment

Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

ASG opens its branch of super-specialty eye hospitals in Noida

ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad

Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake

The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies